Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis-Reference-Cited by-同舟云学术

Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis

Published:2024-09-07 Issue: Volume: Page:
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Hayashi Shinya^ORCID,Nakano Naoki,Tsubosaka Masanori,Kamenaga Tomoyuki,Kuroda Yuichi,Matsumoto Tomoyuki,Yamada Hirotaka,Nishimra Keisuke,Ueda Yo,Saegusa Jun,Kuroda Ryosuke

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10067-024-07117-w.pdf

Reference30 articles.

1. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373(9664):659–672

2. Radner H, Smolen JS, Aletaha D (2011) Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 50(2):381–388

3. Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699

4. de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM (2018) Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford) 57(7):1135–1144

5. Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, Isaacs JD, Hyrich KL (2018) Group B-RC: Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 77(10):1405–1412